Travere Therapeutics, Inc.
FILSPARI
IgA Nephropathy (IgAN)
Resolved
175days ago
FDA decision · Jan 13, 2026
What's at stake
The FDA's approval decision on FILSPARI for IgA Nephropathy (IgAN) is due Jan 13, 2026. A green light opens the market; a complete response letter (CRL) usually sinks the stock.
Primary source
· SEC 8-K
verified 15h ago
“The Company’s PDUFA target action date for its sNDA seeking full approval for FILSPARI in FSGS is January 13, 2026.”